NASDAQ$VSTM
Verastem Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Verastem Oncology reported financial results for the second quarter of 2022 and highlighted recent company progress.
Verastem Oncology reported total revenue of $0.0 million for the three months ended June 30, 2022. The net loss for the quarter was $22.0 million, or $0.12 per share. The company ended the quarter with $94.3 million in cash, cash equivalents and investments.
- Announced findings from the interim analysis of RAMP 201 trial in low-grade serous ovarian cancer.
- Advanced broader development program, including being honored by the Pancreatic Cancer Network as the first recipient of their Therapeutic Accelerator Award.
- U.S Patent and Trademark Office has granted Patent No. 11,400,090 which covers the novel, intermittent twice-weekly dosing regimen used in the VS-6766 development program.
- With approximately 80% of patients in the RAMP 201 study remaining on study treatment with a median duration of follow-up of four months, data from the interim analysis were not mature enough to make a final decision on the go forward treatment regimen and the trial continues with all four cohorts.
Headline financials
Revenue & EPS history
Verastem · Revenue · Quarterly
$2.6M
Forward guidance
Verastem Oncology expects that it has a cash runway until at least 2025 to deliver on the current programs for VS-6766 and defactinib, including expenditures and development in LGSOC and KRAS mutant NSCLC.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-1.0%
Avg return
Earnings day
-0.9%
Avg return
5 days after
+7.3%
Avg return
30 days after
44%
24 / 54 earnings
Positive
+26.9%
Q4 2021
Best reaction
-54.5%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.2% | -23.0% | -38.4% | |
| Q4 2025 | +6.2% | +10.0% | -3.1% | |
| Q3 2025 | -2.9% | +3.6% | +27.0% | |
| Q2 2025 | +19.9% | +42.7% | +91.6% | |
| Q1 2025 | +0.0% | -1.4% | -25.7% | |
| Q4 2024 | -2.5% | -6.2% | -15.8% | |
| Q3 2024 | -3.7% | +19.3% | +51.1% | |
| Q2 2024 | +5.9% | +12.2% | +8.1% | |
| Q1 2024 | +3.9% | +15.4% | -70.2% | |
| Q4 2023 | +2.4% | +5.3% | +5.2% | |
| Q3 2023 | -5.5% | -9.6% | +4.2% | |
| Q2 2023 | -2.2% | -4.0% | -3.8% | |
| Q1 2023 | +2.4% | -4.8% | +121.4% | |
| Q4 2022 | -4.4% | +2.2% | -13.3% | |
| Q3 2022 | +0.0% | +2.6% | +12.8% | |
| Q2 2022 | +1.7% | +6.7% | +2.5% | |
| Q1 2022 | -4.0% | -14.3% | +13.5% | |
| Q4 2021 | +26.9% | +20.2% | +26.9% | |
| Q3 2021 | -3.5% | -3.9% | -15.1% | |
| Q2 2021 | -10.8% | -5.6% | -17.0% | |
| Q1 2021 | -5.1% | -0.3% | +49.2% | |
| Q4 2020 | +2.5% | -0.4% | +12.6% | |
| Q3 2020 | +17.2% | +26.2% | +91.8% | |
| Q2 2020 | -2.0% | -0.7% | -20.3% | |
| Q1 2020 | -54.5% | -57.6% | -57.6% | |
| Q4 2019 | -38.3% | -45.3% | +0.7% | |
| Q3 2019 | -18.8% | -18.0% | -0.8% | |
| Q2 2019 | -6.7% | -9.3% | -16.0% | |
| Q1 2019 | -31.7% | -24.6% | -37.2% | |
| Q4 2018 | +12.8% | +4.7% | -8.4% | |
| Q3 2018 | +12.4% | -0.2% | -12.8% | |
| Q2 2018 | +12.7% | +4.8% | +16.9% | |
| Q1 2018 | -2.3% | -3.9% | +21.4% | |
| Q4 2017 | -4.8% | -8.5% | +14.6% | |
| Q3 2017 | -6.5% | -2.3% | +11.8% | |
| Q2 2017 | -7.0% | -21.4% | +29.0% | |
| Q1 2017 | +15.5% | +17.0% | +3.4% | |
| Q4 2016 | +14.5% | +31.0% | +29.7% | |
| Q3 2016 | +0.0% | +10.6% | +4.4% | |
| Q2 2016 | -0.7% | -4.4% | -1.5% | |
| Q1 2016 | +2.1% | — | — | |
| Q4 2015 | +8.7% | — | — | |
| Q3 2015 | -0.9% | — | — | |
| Q2 2015 | +11.1% | — | — | |
| Q1 2015 | +2.3% | — | — | |
| Q4 2014 | +0.3% | — | — | |
| Q3 2014 | +0.9% | — | — | |
| Q2 2014 | -3.2% | — | — | |
| Q1 2014 | +0.7% | — | — | |
| Q4 2013 | +0.7% | — | — | |
| Q3 2013 | -5.3% | — | — | |
| Q2 2013 | +0.1% | — | — | |
| Q1 2013 | -0.3% | — | — | |
| Q1 2012 | -2.5% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro